FindTrial
Sign In

A real-world clinical study of the aiding role of intestinal microbiome-associated metabolite in the diagnosis of early colorectal cancer and adenoma and the prediction value of recurrence after endoscopic treatment

A real-world clinical study of the aiding role of intestinal microbiome-associated metabolite in the diagnosis of early colorectal cancer and adenoma and the prediction value of recurrence after endoscopic treatment

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058078
Enrollment
Unknown
Registered
2022-03-29
Start date
2022-03-28
Completion date
Unknown
Last updated
2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal adenoma and early carcinoma

Interventions

modeling group:taking feces and blood sample
validation group :taking blood sample

Sponsors

First Medical Center of Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patient aged >=18 years; 2. Colonoscopy revealed polypoid lesions, which were pathologically suggestive of colorectal adenoma or low/high grade intraepithelial neoplasia; 3. Plan to receive endoscopic treatment in our hospital; 4. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe cardiopulmonary diseases, such as myocardial infarction and severe heart failure; 2. Coagulation dysfunction; 3. Mental abnormality can not cooperate with the examination; 4. Other contraindications of endoscopic examination; 5. History of taking antibiotics within the past two weeks.

Design outcomes

Primary

MeasureTime frame
accuracy;sensitivity;specificity;—

Countries

China

Contacts

Public ContactChai Ningli
xjyyjx33@163.com+86 15011362982

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026